Cann Group Ltd. operates research and development and cultivation facilities to grow medicinal cannabis. The company is headquartered in Melbourne, Victoria. The firm is a developer and supplier of cannabis, cannabis resin and medicinal cannabis products. The company also owns Satipharm, a Europe-based business licensed to manufacture, develop and market the Gelpell delivery system for cannabinoids. The firm has established research and cultivation facilities in Melbourne and is developing a cultivation and manufacturing facility near Mildura, Victoria. The firm focuses on plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The firm is commercializing a range of imported and locally sourced and manufactured medicinal cannabis products.
Cann Group (ASX: CAN)
- Home
- Cann Group (ASX: CAN)
Here are the latest articles on Cann Group (ASX: CAN)
Cann Group poised for growth as demand for locally produced cannabis surges
July 5, 2023
Australia has made a groundbreaking decision by becoming the first country to legalise the clinical prescribing of MDMA (ecstasy) and psilocybin (magic mushrooms) for the treatment of specific mental health disorders, including PTSD and treatment-resistant depression. Setting Australia apart as the pioneer in adopting psychoactive-based treatments for mental health, as of 1 July, authorised psychiatrists
Cann Group strengthens position with variation agreement in medicinal cannabis sector
June 21, 2023
The medicinal cannabis industry in Australia has been rapidly gaining momentum, reaching an estimated value of approximately $245 million in 2022 and is projected to maintain a strong CAGR of 16.71% from 2023 to 2027. While the availability of cannabis for general use remains restricted in Australia, the nation continues to attract cannabis manufacturing companies
Cannabis company comeback, Cann Group’s busy few months
February 1, 2023
This quarter has been a busy one for Australian cannabis distributor Cann Group (ASX: CAN), evident in the Company’s sales revenue figures increasing a tidy 91% from the same quarter last year. But with the release of disappointing trial results following its CBD placebo-controlled study, the Company has had to work against a backdrop of
Cann’d: clinical trials show no difference between cannabis capsules and placebo
January 19, 2023
Since the easing of regulatory red tape and wider societal acceptance of utilising cannabis for its medical properties, the medicinal cannabis industry has become an intense battleground as researchers have raced towards commercial products. In the case of Cann Group (ASX: CAN) though, they might have just triggered a land mine. Undertaking any form of
Cann Group praying to recover $3.6m lost to internet scammers
February 8, 2021
In an incident which can only be described with a 🤦♂️, shareholders of cannabis company Cann Group (ASX: CAN) are understandably frustrated in the Company which has reported a cybersecurity breach that resulted in $3.6 million going missing. The incident was discovered on 4 February and immediately led Cann to enter a trading halt as
‘Please explain’, social media post leads to flurry of ‘unusual’ cannabis trading
January 7, 2020
Medical cannabis producer, Cann Group Limited (ASX: CAN) have announced this morning their response to yesterday’s price query from the ASX that lead to the company being placed in a trading halt soon after. The regulator probed the company to ‘please explain’ yesterday’s trading activity which saw almost a 19% increase in trading price and
Recent Articles
